RNS Number : 5303U
23 December 2011
For immediate release 23 December 2011
("Abcam" or "the Company")
PDMR dealing: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), a global leader in the supply of protein research tools, announces that following completion of three years of continued employment since the award of Matching Shares under the Share Incentive Plan, the risk of forfeiture attached to these shares has now been removed, resulting in an increase in the beneficial holding of the following PDMR:
Name Matching Shares Date of transfer Total subsequent Percentage
now transferred to beneficial beneficial of share
to beneficial ownership holding capital
Philippe Cotrel 135 23 Dec 2011 6,359 0.003%
----------------- ----------------- ----------------- -----------
For further information please contact:
Abcam + 44 (0) 1223 696 000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Jessica Fontaine
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level, which is essential in understanding health and disease.
Headquartered in Cambridge (UK), Abcam has subsidiary offices in Bristol (UK), Cambridge, MA (USA), Eugene, OR (USA), Tokyo (Japan) and Hong Kong (China) allowing it to serve a global customer base in over 85 countries. Abcam employs over 325 staff across its six operating companies.
Abcam now has an online catalogue of over 82,000 products sourced from over 300 suppliers. The catalogue includes a growing range of non-primary antibody products such as secondaries, proteins, peptides, lysates, immunoassays and other kits. Products are available for life science research and distributed to academic and commercial users. A highly developed eCommerce platform, which includes regional websites for the Chinese and Japanese markets, allows customers to access up-to-date and detailed technical product data sheets at the Company's website www.abcam.com.
Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company's vision is to be the leading provider of protein research tools globally.
This information is provided by RNS
The company news service from the London Stock Exchange